BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 17878099)

  • 1. [Immunotherapy: a new alternative treatment for head and neck squamous cell carcinoma].
    Bron L; Romero P
    Bull Cancer; 2007 Sep; 94(9):793-7. PubMed ID: 17878099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunotherapy for head and neck squamous cell carcinoma].
    Bron L; Romero P
    Rev Med Suisse; 2006 Oct; 2(81):2216-9. PubMed ID: 17076151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in head and neck cancer: current practice and future possibilities.
    Agada FO; Alhamarneh O; Stafford ND; Greenman J
    J Laryngol Otol; 2009 Jan; 123(1):19-28. PubMed ID: 18761763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cells and HNSCC: a potential treatment option? (Review).
    Dunn G; Oliver KM; Loke D; Stafford ND; Greenman J
    Oncol Rep; 2005 Jan; 13(1):3-10. PubMed ID: 15583794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed?
    Ferris RL
    ORL J Otorhinolaryngol Relat Spec; 2004; 66(6):332-40. PubMed ID: 15668533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dendritic cell based hybrid cell vaccine generated by electrofusion for immunotherapy strategies in HNSCC.
    Weise JB; Maune S; Görögh T; Kabelitz D; Arnold N; Pfisterer J; Hilpert F; Heiser A
    Auris Nasus Larynx; 2004 Jun; 31(2):149-53. PubMed ID: 15121224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Future Prospects on neoplasm antigen vaccine therapy for patients with head and neck squamous cell carcinoma].
    Eura M
    Nihon Jibiinkoka Gakkai Kaiho; 2002 Mar; 105(3):201-7. PubMed ID: 12014346
    [No Abstract]   [Full Text] [Related]  

  • 8. Cytokines in head and neck cancer.
    Pries R; Wollenberg B
    Cytokine Growth Factor Rev; 2006 Jun; 17(3):141-6. PubMed ID: 16540364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune alterations and immunotherapy prospects in head and neck cancer.
    Varilla V; Atienza J; Dasanu CA
    Expert Opin Biol Ther; 2013 Sep; 13(9):1241-56. PubMed ID: 23789839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma.
    Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
    Mol Ther; 2006 Jan; 13(1):183-93. PubMed ID: 16125469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunology of head and neck cancers.
    Newbill ET; Johns ME
    Crit Rev Clin Lab Sci; 1983; 19(1):1-25. PubMed ID: 6201320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Treatment Options in Head and Neck Cancer.
    Schuler PJ; Laban S; Doescher J; Bullinger L; Hoffmann TK
    Oncol Res Treat; 2017; 40(6):342-346. PubMed ID: 28521322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transference of cell mediated immunity in patients with head and neck cancer.
    Vetto RM; Burger DR
    Laryngoscope; 1978 Jan; 88(1 Pt 2 Suppl 8):79-82. PubMed ID: 304143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs.
    Cavalieri S; Rivoltini L; Bergamini C; Locati LD; Licitra L; Bossi P
    Cancer Treat Rev; 2018 Apr; 65():78-86. PubMed ID: 29574334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of DNA-hsp65 immunotherapy for advanced squamous cell carcinoma of the head and neck.
    Michaluart P; Abdallah KA; Lima FD; Smith R; Moysés RA; Coelho V; Victora GD; Socorro-Silva A; Volsi EC; Zárate-Bladés CR; Ferraz AR; Barreto AK; Chammas MC; Gomes R; Gebrim E; Arakawa-Sugueno L; Fernandes KP; Lotufo PA; Cardoso MR; Kalil J; Silva CL
    Cancer Gene Ther; 2008 Oct; 15(10):676-84. PubMed ID: 18535616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigenic epitopes of three tumor-associated antigens of well-differentiated squamous cell carcinoma of the larynx for use in monitoring patients in specific active immunochemotherapy trials.
    Hollinshead AC
    Cancer Detect Prev; 1987; 10(3-4):153-8. PubMed ID: 2436778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of an autologous cell system for immunotherapy of squamous cell carcinoma of the head and neck.
    Mayer A; Andratschke M; Pauli C; Graefe H; Kristina K; Wollenberg B
    Anticancer Res; 2005; 25(6B):4075-80. PubMed ID: 16309201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.
    Moy JD; Moskovitz JM; Ferris RL
    Eur J Cancer; 2017 May; 76():152-166. PubMed ID: 28324750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients.
    Victora GD; Socorro-Silva A; Volsi EC; Abdallah K; Lima FD; Smith RB; Moyses RA; Zárate-Bladés CR; Michaluart P; Silva CL; Kalil J; Coelho V
    Cancer Gene Ther; 2009 Jul; 16(7):598-608. PubMed ID: 19197326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET monitoring of therapy response in head and neck squamous cell carcinoma.
    Schöder H; Fury M; Lee N; Kraus D
    J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.